



VIA DHL EXPRESS

May 1, 2008

Cody C. Wiberg  
Executive Director  
Minnesota Board of Pharmacy  
2829 University Avenue S.E., #530  
Minneapolis, MN 55414-3251

**GlaxoSmithKline**  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709-3398  
Tel. 919 483 2100  
www.gsk.com

Dear Mr. Wiberg:

Pursuant to applicable Minnesota state law, SmithKline Beecham Corporation d/b/a GlaxoSmithKline ("GSK") submits on behalf of **Reliant Pharmaceuticals** ("Reliant") to the Minnesota Board of Pharmacy Reliant's 2007 report of its payments, reimbursements or other compensation paid by Reliant to individual practitioners. The attached report reflects payments made by Reliant to Minnesota practitioners for consulting services and services provided in connection with educational programs.

On December 18, 2007, GSK acquired Reliant Pharmaceuticals ("Reliant"). GSK has attempted in good faith to capture and report transactions pursuant to applicable Minnesota state law (and related guidance). It should be noted, however, that this report is derived from information received from Reliant; thus, GSK is relying upon Reliant's systems and sources for completeness and accuracy. Future reports will be submitted under one cover.

Reliant had arrangements with foundations, universities, contract research organizations and other business entities to conduct research or provide information under which payments may have been made by such institutions to Minnesota practitioners. Given that compensation to Minnesota practitioners in these cases was not from Reliant, payments to these entities are not reflected on the attached report. Similarly, the report does not identify payments to sponsors of independent medical conferences, continuing medical education programs, professional meetings or other educational programs where Reliant may have provided funds through a grant to an organization, but does not pay a practitioner (e.g., educational grants).

Although Minnesota law states that the reports are public data, GSK considers the information in this report to be confidential and propriety information. Reliant did not publicly release this information or the company documents that were used to create this report. Further, release of the entries in this report or the aggregate information in this report may give GSK's competitors information that may undermine its relationship with its contractors and consultants and enable competitors to gain a business advantage.

If the Minnesota Board of Pharmacy has any questions regarding this letter or the information contained in our report, please contact Michelle West at 215-751-6526.

Sincerely,

Arjun Rajaratnam,  
Vice President & Compliance Officer U.S. Pharmaceuticals